AAAAAA
Results: 101-125/640
Authors:
HOLT DW
Citation: Dw. Holt, CYCLOSPORINE METHODOLOGY FOLLOWING THE CHATEAU-LAKE-LOUIS CONSENSUS MEETING, Therapie, 52(4), 1997, pp. 313-316
Authors:
BIZOLLON A
HAMDANE R
Citation: A. Bizollon et R. Hamdane, QUALITY-CONTROL UPDATE - A NECESSITY FOR GBEA, Therapie, 52(4), 1997, pp. 317-320
Authors:
SEYDOUX C
GOY JJ
Citation: C. Seydoux et Jj. Goy, A SPECIFIC MONOCLONAL-ANTIBODY FOR CYCLOS PORINE MEASUREMENT - THE CLINICIAN POINT-OF-VIEW, Therapie, 52(4), 1997, pp. 321-325
Authors:
GULBIS B
VANDERHEIJDEN J
VANAS H
THIRY P
Citation: B. Gulbis et al., HEART AND LIVER-TRANSPLANT - THERAPEUTIC MONITORING OF CYCLOSPORINE BY 2 METHODS, MFPIA AND EMIT, Therapie, 52(4), 1997, pp. 327-328
Authors:
SIMON N
BARRE J
JOLLIET P
URIEN S
TILLEMENT JP
Citation: N. Simon et al., MEDIATORS INVOLVED IN CYCLOSPORINE-A NEPH ROTOXICITY, Therapie, 52(4), 1997, pp. 329-333
Authors:
BILLAUD EM
GUILLEMAIN R
CHEVALLIER P
AMREIN C
GUINVARCH A
COUETIL JP
Citation: Em. Billaud et al., IMMUNOSUPPRESSION IN CYSTIC-FIBROSIS, Therapie, 52(4), 1997, pp. 335-339
Authors:
MULLER MM
VOGL M
GRIESMACHER A
Citation: Mm. Muller et al., MYCOPHENOLIC-ACID MONITORING IN HTX PATIENTS - A PRELIMINARY-REPORT, Therapie, 52(4), 1997, pp. 341-344
Authors:
GARRAFFO R
Citation: R. Garraffo, PHARMACOKINETIC AND THERAPEUTIC MONITORIN G OF TACROLIMUS, Therapie, 52(4), 1997, pp. 345-352
Authors:
HUMBERT H
Citation: H. Humbert, VARIABILITY OF THE BIOAVAILABILITY OF CYC LOSPORINE - BENEFIT OF THE NEORAL(R) FORMULATION, Therapie, 52(4), 1997, pp. 353-357
Authors:
THERY C
PRAT A
ASSEMAN P
BAUCHART JJ
MICHON P
LESENNE M
JUDE B
Citation: C. Thery et al., POSTMENOPAUSAL HORMONAL REPLACEMENT THERA PY AND THE RISK OF VENOUS THROMBOEMBOLIC DISEASE, Therapie, 52(3), 1997, pp. 165-168
Authors:
CHARANSONNEY OL
LIEVRE M
LAVILLE M
LION L
DEROBERT E
VISELE N
DECOURT S
DERUSUNAN MP
LUCIANI J
VASMANT D
BOISSEL JP
GRUNFELD JP
Citation: Ol. Charansonney et al., THE EUREVIE STUDY - CONTRASTING EFFECT OF PIRETANIDE AND THIAZIDES INMILD-TO-MODERATE HYPERTENSION, Therapie, 52(3), 1997, pp. 169-177
Authors:
MEILHAC B
MONTESTRUC F
AUBIN F
DJIAN F
ROUFFY J
Citation: B. Meilhac et al., DOUBLE-BLIND RANDOMIZED TRIAL OF NICERGOL IN AND NAFTIDROFURYL ON QUALITY-OF-LIFE IN OBLITERATIVE ARTERIAL-DISEASE OF THE LOWER-LIMBS WITH INTERMITTENT CLAUDICATION, Therapie, 52(3), 1997, pp. 179-186
Authors:
BOBRIE G
DUTREYDUPAGNE C
VAUR L
DUBROCA I
ELKIK F
CHATELLIER G
MENARD J
Citation: G. Bobrie et al., DURATION OF ACTION OF 2 ACE-INHIBITORS US ING SELF BLOOD-PRESSURE MEASUREMENT, Therapie, 52(3), 1997, pp. 187-193
Authors:
MILON H
BALEYDIER A
Citation: H. Milon et A. Baleydier, A COMPARISON OF THE ANTIHYPERTENSIVE AND METABOLIC EFFECTS OF LISINOPRIL-20-MG HYDROCHLOROTHIAZIDE-12.5-MG FIXED COMBINATION WITH CAPTOPRIL-50-MG/HYDROCHLOROTHIAZIDE-25-MG FIXED COMBINATION/, Therapie, 52(3), 1997, pp. 195-205
Authors:
SEROUSSI B
GERONDEAU N
MORICE V
BOISVIEUX JF
Citation: B. Seroussi et al., COMPARATIVE-EVALUATION OF FRENCH DRUG DAT A-BANKS, Therapie, 52(3), 1997, pp. 207-212
Authors:
PELISSIER AL
LEONETTI G
VILLANI P
CIANFARANI F
BOTTA A
Citation: Al. Pelissier et al., CANNABIS - REVIEW OF TOXICOKINETICS AND B IOMONITORING METHODOLOGY, Therapie, 52(3), 1997, pp. 213-218
Authors:
CORVAISIER S
BLEYZAC N
CONFESSON MA
BUREAU C
MAIRE P
Citation: S. Corvaisier et al., A POPULATION-MODEL FOR AMIKACIN IN NON-IN SULIN-DEPENDENT DIABETIC-PATIENTS USING THE NONPARAMETRIC SOFTWARE NPEM2, Therapie, 52(3), 1997, pp. 219-226
Authors:
AYMARD N
BALDACCI C
LEYRIS A
SMAGGHE PO
TRIBOLET S
VACHERON MN
VIALA A
CAROLI F
Citation: N. Aymard et al., NEUROLEPTIC-RESISTANT SCHIZOPHRENIC-PATIENTS TREATED BY CLOZAPINE - CLINICAL EVOLUTION, PLASMA AND RED-BLOOD-CELL CLOZAPINE AND DESMETHYLCLOZAPINE LEVELS, Therapie, 52(3), 1997, pp. 227-232
Citation: 15TH CONSENSUS CONFERENCE IN INTENSIVE-CA RE AND EMERGENCY-MEDICINE -CATECHOLAMINE USE DURING SEPTIC SHOCK (ADULTS AND CHILDREN), Therapie, 52(3), 1997, pp. 233-237
Authors:
LIEVRE M
CUCHERAT M
Citation: M. Lievre et M. Cucherat, NIFEDIPINE AND CORONARY-HEART-DISEASE - R EASONS FOR CONTROVERSY (VOL52, PG 37, 1997), Therapie, 52(3), 1997, pp. 239-240
Authors:
DOUTRE MS
BEYLOT C
Citation: Ms. Doutre et C. Beylot, CUTANEOUS COMPLICATIONS OF MESOTHERAPY, Therapie, 52(2), 1997, pp. 93-96
Authors:
CASTOT A
DJEZZAR S
DELEAU N
GUILLOT B
EFTHYMIOU ML
Citation: A. Castot et al., PHARMACOVIGILANCE OFF THE BEATEN TRACK - DRUG SURVEILLANCE OF HERBAL MEDICINES, Therapie, 52(2), 1997, pp. 97-103
Authors:
MONTASTRUC JL
BAGHERI H
GERAUD T
LAPEYREMESTRE M
Citation: Jl. Montastruc et al., DRUG SURVEILLANCE AND SIDE-EFFECTS OF SEL F-MEDICATION, Therapie, 52(2), 1997, pp. 105-110
Authors:
BERTHELOT JM
GLEMAREC J
CHIFFOLEAU A
MAUGARS Y
PROST A
Citation: Jm. Berthelot et al., TREATMENT WITH LOW-DOSE METHOTREXATE IN R HEUMATOID-ARTHRITIS - RISK-FACTORS FOR SERIOUS SIDE-EFFECTS, Therapie, 52(2), 1997, pp. 111-116
Authors:
BLAYAC JP
HILLAIREBUYS D
PEYRIERE H
Citation: Jp. Blayac et al., DRUG SURVEILLANCE OF NEW ANTIDEPRESSANTS - EVALUATION OF NEUROBEHAVIORAL IMPACT, Therapie, 52(2), 1997, pp. 117-122